Recombinant erythropoietin - XTL

Drug Profile

Recombinant erythropoietin - XTL

Alternative Names: EPO - XTL; rHuEPO - XTL

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator Bio-GAL
  • Developer XTL Biopharmaceuticals
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoietin receptor agonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 02 May 2016 Phase-I clinical trials in Multiple myeloma in Israel (Parenteral)
  • 02 Jun 2014 XTL plans a phase IIb trial in Multiple myeloma
  • 29 Mar 2012 XTL Biopharmaceuticals plans a phase II trial for Multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top